BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2021 8:31:02 AM | Browse: 543 | Download: 1078
 |
Received |
|
2020-11-23 15:03 |
|
Peer-Review Started |
|
2020-11-23 15:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-01-07 01:33 |
|
Revised |
|
2021-01-12 08:23 |
|
Second Decision |
|
2021-02-25 12:58 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-02-26 19:48 |
|
Articles in Press |
|
2021-02-26 19:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-03-09 04:30 |
|
Publish the Manuscript Online |
|
2021-03-11 08:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Angela Lamarca, Mauro Cives, Louis de Mestier, Joakim Crona, Francesca Spada, Kjell Öberg, Marianne Pavel and Teresa Alonso-Gordoa |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Angela Lamarca, MD, MSc, PhD, Senior Lecturer, Department of Medical Oncology, European Neuroendocrine Tumor Society Centre of Excellence, The Christie NHS Foundation Trust, University of Manchester, Manchester M20 4BX, United Kingdom. angela.lamarca@nhs.net |
| Key Words |
Neuroendocrine tumour; Small bowel; Survey; Third-line; Advanced; Practice |
| Core Tip |
Our survey delineates a possible treatment algorithm in patients with advanced small bowel neuroendocrine tumour (SBNET). While somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT) and everolimus are usually considered preferred first, second and third-line options respectively, chemotherapy is generally used when all other available treatments have failed. Locoregional therapies appear particularly useful when facing patients with functioning tumours, but their use is mainly limited to after at least two prior lines of treatment. We were also able to identify relevant unanswered questions in the field of advanced SBNET treatment, mainly in regards to the role of maintenance SSA after PRRT for non-functioning tumours. Multiple factors were identified as relevant at time of decision making; among them, Ki-67, rate of progression, tumour functionality and tumour burden may have a key role in helping physicians tailoring the treatment. Based on this, we would encourage for treatment decisions to be made within a multidisciplinary setting. |
| Publish Date |
2021-03-11 08:31 |
| Citation |
Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd line treatment. World J Gastroenterol 2021; 27(10): 976-989 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i10/976.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i10.976 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
